JP Morgan Chase
TRVI icon

JP Morgan Chase’s Trevi Therapeutics TRVI Stock Holding History

JP Morgan Chase’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$790K Buy
70,631
+11,156
+19% +$125K ﹤0.01% 4741
2025
Q4 		$745K Buy
59,475
+660
+1% +$7.63K ﹤0.01% 4785
2025
Q3 		$538K Buy
58,815
+4,473
+8% +$33.5K ﹤0.01% 4981
2025
Q2 		$297K Sell
54,342
-9,110
-14% -$56.7K ﹤0.01% 5033
2025
Q1 		$399K Sell
63,452
-158,212
-71% -$755K ﹤0.01% 4909
2024
Q4 		$913K Buy
221,664
+121,147
+121% +$388K ﹤0.01% 4701
2024
Q3 		$336K Buy
100,517
+69,167
+221% +$206K ﹤0.01% 5143
2024
Q2 		$93.4K Buy
31,350
+5,887
+23% +$16.4K ﹤0.01% 5544
2024
Q1 		$87.8K Sell
25,463
-1,520
-6% -$3.39K ﹤0.01% 5726
2023
Q4 		$36.2K Sell
26,983
-2
-0% -$3 ﹤0.01% 6104
2023
Q3 		$58.8K Sell
26,985
-6,189
-19% -$14K ﹤0.01% 5738
2023
Q2 		$79.3K Buy
+33,174
New +$83.6K ﹤0.01% 5563
2020
Q4 		– Sell
-3
Closed – – 5933
2020
Q3 		$0 Hold
3
– – ﹤0.01% 5783
2020
Q2 		$0 Buy
+3
New +$11 ﹤0.01% 5703

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

JP Morgan Chase's TRVI Position: Q1 2026 in Review

JP Morgan Chase increased its Trevi Therapeutics (TRVI) stake by 19% in Q1 2026, buying an estimated $125K and bringing the position to 70,631 shares worth $790K. The position accounts for ﹤0.01% of the portfolio, ranked #4741.

JP Morgan Chase first reported a position in TRVI in Q2 2020 and has held it in 14 quarters since. The position peaked at $913K in Q4 2024. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • JP Morgan Chase held 70,631 shares of Trevi Therapeutics worth $790K as of Q1 2026.
  • JP Morgan Chase bought 11,156 Trevi Therapeutics shares in Q1 2026, an estimated $125K.
  • Trevi Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4741 holding.
  • JP Morgan Chase first reported a position in Trevi Therapeutics in Q2 2020 and has held it in 14 quarters since.
  • JP Morgan Chase's Trevi Therapeutics position peaked at $913K in Q4 2024.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.